Denali Therapeutics Inc (DNLI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.00B
Last updated: Nov 17, 2026 at 11:04 AM ET
Denali Therapeutics Inc (DNLI) Stock Forecast
Analysts expect Denali Therapeutics (DNLI) to earn -$2.05 per share in the fiscal year ending Dec 31, 2026, on revenue of $54.02M. Of 20 analysts, 19 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 5 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 20 ratings average 1.95, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 95% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 10.0% |
| Buy | 17 | 85.0% |
| Hold | 1 | 5.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 20
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates rise 202.7%.
- Fiscal year ending Dec 31, 2026
- -$2.05
- EPS consensus, revenue $54.02M
- Fiscal year ending Dec 31, 2027
- -$2.23
- EPS consensus, revenue $163.54M
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$2.05 | -$2.70 to -$1.50 | 7 | $54.02M | $51.38M to $76.72M | 18 |
| Dec 31, 2027 | -$2.23 | -$2.66 to -$1.50 | 8 | $163.54M | $78.42M to $312.30M | 19 |
Quarterly Estimates
The EPS consensus falls from -$0.63 for the quarter ending Dec 31, 2026 to -$0.64 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.63 | -$0.74 to -$0.48 | 22 | $32.41M | $12.92M to $79.19M | 20 |
| Mar 31, 2027 | -$0.64 | -$0.69 to -$0.58 | 2 | $39.89M | $31.70M to $51.27M | 7 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 12 upward and 2 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 5 | 1 |
| Fiscal year ending Dec 31, 2027 | 5 | 1 |
| Quarter ending Mar 31, 2027 | 2 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$2.37.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$2.05 | -$2.23 | -$2.22 | -$2.35 | -$2.37 | N/A |
| Fiscal year ending Dec 31, 2027 | -$2.23 | -$2.42 | -$2.42 | -$2.43 | -$2.53 | N/A |
| Quarter ending Mar 31, 2027 | -$0.64 | -$0.70 | -$0.69 | -$0.69 | -$0.73 | N/A |
Frequently Asked Questions About DNLI
What is the DNLI stock forecast?
Consensus analyst estimates put Denali Therapeutics's EPS at -$2.05 for the fiscal year ending Dec 31, 2026, on revenue of $54.02M. The consensus rating from 20 analysts is Buy.
How do analysts rate DNLI stock?
Of 20 analysts covering Denali Therapeutics, 2 rate it Strong Buy, 17 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from DNLI next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.05, with estimates from -$2.70 to -$1.50 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.23, with estimates from -$2.66 to -$1.50 from 8 analysts.
What revenue do analysts expect from Denali Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $54.02M, with estimates from $51.38M to $76.72M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $163.54M, with estimates from $78.42M to $312.30M.
How many analysts cover DNLI?
20 analysts rate Denali Therapeutics stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
DNLI pages: Overview, Earnings, Forecast, Financials, Competitors